A federal court has temporarily restored mail-based access to mifepristone, halting a lower court's order that would have required patients to obtain the medication in person from a health care provider.
The decision represents a brief reprieve for abortion access as legal battles over the medication continue through the court system. Mifepristone, a key component of medication abortion, had been subject to stricter dispensing rules after a lower court moved to reinstate an FDA requirement for in-person visits.
The temporary restoration allows pharmacies to continue mailing the pill to patients during the ongoing litigation. This maintains the status quo that had been in place before the lower court's intervention, which sought to impose the in-person requirement on all mifepristone recipients.
The ruling underscores the volatile legal landscape surrounding abortion medication nationwide. Since the Supreme Court's 2022 decision eliminating the federal constitutional right to abortion, states have adopted wildly different approaches to medication abortion access, and litigation over the drug's availability has accelerated.
The temporary order does not resolve the underlying dispute over whether mifepristone should be distributed by mail or require in-person evaluation. The case will continue through the courts, where broader questions about the FDA's regulatory authority and states' ability to restrict the medication remain unresolved.
For now, patients in states where medication abortion is legal can still access mifepristone through the mail, but advocates warn that the back-and-forth court decisions create uncertainty that may deter both providers and patients from relying on the medication option.
Author Sarah Mitchell: "The courts keep kicking this football down the field while real people trying to access basic health care face mounting chaos."
Comments